Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04777357 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder.

Study acronym: 3112 Ped BPD
StatusRecruiting
PhasePhase 3
SponsorAbbVie
Started2021-04-28
View on ClinicalTrials.gov ↗
Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population and 1.8% of the pediatric population in the United States. The treatment of the depressive episodes of bipolar disorder in the pediatric population has not been as widely studied as the treatment of depressive episodes in bipolar disorder in adults, therefore pharmacotherapeutic options are limited. Given the change in disease state and safety demonstrated in adults with depressive episodes associated with bipolar I disorder, the purpose of this study is to evaluate the change in disease state and safety of cariprazine in the treatment of depressive episodes associated with bipolar I disorder in the pediatric population. Cariprazine is an approved drug for the treatment of depressive episodes in adult participants with bipolar I disorder. Study doctors put participants in 1 of 2 groups, called treatment arms. There is a 1 in 2 chance that a participant will be assigned to placebo. Around 380 Participants ages 10-17 years with bipolar I disorder will be enrolled in approximately 60 sites worldwide. Participants receiving the study drug will receive Dose A or B of Cariprazine based on age and weight. At Week 3, participants with insufficient response will have their dose increased to Dose B or Dose C, while participants with sufficient response will continue receiving the Dose A or B for the remainder of the treatment period. The treatment period will be followed by a safety follow-up (SFU) period for 4 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Amendment record

Amended 94 times since 2021-02-26; most recent filed 2026-07-24. The 50 most recent of 95 record versions are listed below. See every version on ClinicalTrials.gov ↗

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-29.

2026-07-24
Amendment Study Status, Arms and Interventions v94
2026-06-24
Amendment Study Status, Contacts/Locations v93
2026-06-12
Amendment Study Status, Contacts/Locations v92
2026-06-11
Amendment Study Status, Contacts/Locations v91
2026-06-10
Amendment Study Status, Contacts/Locations v90
2026-06-01
Amendment Study Status, Contacts/Locations v89
2026-05-25
Amendment Study Status, Contacts/Locations v88
2026-05-15
Amendment Study Status, Contacts/Locations v87
2026-05-11
Amendment Study Status, Contacts/Locations v86
2026-03-30
Amendment Study Status, Contacts/Locations v85
2026-03-26
Amendment Study Status, Contacts/Locations v84
2026-03-11
Amendment Study Status, Contacts/Locations v83
2026-03-06
Amendment Study Status, Contacts/Locations v82
2026-02-02
Amendment Study Status, Contacts/Locations v81
2026-01-19
Amendment Study Status, Contacts/Locations v80
2025-12-17
Amendment Study Status, Contacts/Locations v79
2025-12-13
Amendment Study Status, Contacts/Locations v78
2025-11-08
Amendment Study Status, Arms and Interventions, Outcome Measures, Contacts/Locations, IPDSharing v77
2025-08-28
Amendment Study Status, Contacts/Locations v76
2025-08-26
Amendment Study Status, Contacts/Locations v75
2025-08-07
Amendment Study Status, Contacts/Locations v74
2025-07-14
Amendment Study Status, Contacts/Locations v73
2025-06-16
Amendment Study Status, Contacts/Locations v72
2025-06-05
Amendment Study Status, Contacts/Locations v71
2025-04-07
Amendment Study Status, Contacts/Locations v70
2025-03-24
Amendment Study Status, Contacts/Locations v69
2025-03-17
Amendment Study Status, Contacts/Locations v68
2025-03-04
Amendment Study Status, Contacts/Locations v67
2025-03-03
Amendment Study Status, Contacts/Locations v66
2025-02-11
Amendment Study Status, Contacts/Locations v65
2025-02-07
Amendment Study Status, Contacts/Locations v64
2025-01-08
Amendment Study Status v63
2024-11-19
Amendment Study Identification, Study Status, Contacts/Locations v62
2024-10-28
Amendment Study Status, Contacts/Locations v61
2024-10-04
Amendment Study Status, Contacts/Locations v60
2024-09-26
Amendment Study Status, Contacts/Locations, IPDSharing v59
2024-06-18
Amendment Study Identification, Study Status, Outcome Measures, Eligibility, Contacts/Locations v58
2024-03-05
Amendment Study Status, Contacts/Locations v57
2024-03-04
Amendment Study Status v56
2024-02-23
Amendment Study Status, Contacts/Locations v55
2024-02-13
Amendment Study Status, Contacts/Locations v54
2024-02-01
Amendment Study Status, Contacts/Locations v53
2024-01-30
Amendment Study Status, Contacts/Locations v52
2023-11-14
Amendment Study Status, Contacts/Locations v51
2023-11-13
Amendment Study Status, Contacts/Locations v50
2023-11-08
Amendment Study Status, Contacts/Locations v49
2023-11-07
Amendment Study Status, Contacts/Locations v48
2023-10-09
Amendment Study Status, Contacts/Locations v47
2023-08-24
Amendment Study Identification, Study Status, Outcome Measures, Eligibility, Contacts/Locations v46
2023-05-22
Amendment Study Status, Contacts/Locations v45
Trial Details
NCT Number NCT04777357
Lead Sponsor AbbVie
Conditions Depression, Bipolar I Disorder
Enrollment 380 participants
Start Date 2021-04-28
Primary Completion 2027-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2026-07-27